Zentek has exclusive worldwide rights to commercialize a rapid, saliva-based COVID-19 antigen testing technology.
This technology has been developed by a team of researchers at McMaster University under the guidance of Drs. Yingfu Li, John Brennan and Leyla Soleymani, who are recognized as global leaders in biosensing technologies, and their applications as point of care (POC) diagnostics.
The Aptamers are single-stranded DNA molecules capable of binding specifically with target molecules called antigens to detect if a person has COVID-19.
Zentek is currently adopting its Detection Technology for commercial prototyping readiness.
The advantages of Zentek's aptamer technology are:
- Simplicity & Comfort – uses saliva rather than a nasal swab reducing aversion to testing and risk of error in the sampling process
- Accuracy – impedance technology rather than lateral flow allows for sensitivity equivalent to a 36 count Rt PCR
- Mobility – simple hardware lends itself to easy transport and high throughput, point-of-care testing
- Speed – results in under 10 minutes
- Low Cost – aptamers can be developed more quickly and cost effectively compared to antibodies allowing us to be highly competitive compared to currently available rapid detection tests now and into the future
- Scalability – new aptamers can be developed to detect numerous other pathogens giving our technology the ability to enhance safety and empower businesses, governments and our healthcare providers well beyond COVID
We believe this an unmatched combination compared to what is available in the market today.
The global economy will benefit from mobile, fast, highly accurate and inexpensive testing and we expect this innovative technology to help facilitate this, including the ability to rapidly adapt new variants and other pathogens into the test.
Detection News
View all newsMay 19, 2022
Zentek’s Rapid Diagnostic Platform Receives Two NSERC Grants Towards Commercialization
Read now
November 9, 2021
Zentek Provides Update on Rapid Detection Technology
Read now
June 17, 2021
ZEN Graphene Solutions Announces Exclusive Worldwide Rights to Commercialize Rapid, Saliva-Based COVID-19 Antigen Testing Technology
Read now
Get In Touch
Commercial Partners
Are you interested in our technology to enhance your product offering - or have an innovation that fits well with our focus areas and would like to work together?
Contact
Ryan Shacklock
rshacklock@zentek.comSales & Partnerships
Are you interested in purchasing our products or discussing sales?
Contact
Ryan Shacklock
rshacklock@zentek.comRegulatory
Are you looking to discuss regulatory affairs or quality assurance?
Contact
Regulatory
regulatory@zentek.comResearch Community
Are you a researcher focused on new and innovative nanotechnologies and looking for a highly engaged development partner?
Contact
Adam MacIntosh
amacintosh@zentek.comGovernment
Are you a member of federal, provincial or international governments looking to invest, fund, collaborate, partner with, support, or help advance next-gen healthcare?
Contact
Monique Manaigre
mmanaigre@zentek.comExecutive & Administrative Inquiries
Are you looking for other company information?
Contact
Information
info@zentek.comInvestor Relations
Are you looking to discuss investor relations?
Contact
investorrelations@zentek.com